Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas

Journal of Nuclear Medicine

Volumn 51, Issue 10, 2010, Pages 1532-1538

  Fueger, Barbara J ^a   Czernin, Johannes ^a   Cloughesy, Timothy ^a   Silverman, Daniel H ^a   Geist, Cheri L ^a   Walter, Martin A ^a   Schiepers, Christiaan ^a   Nghiemphu, Phioanh ^a   Lai, Albert ^a   Phelps, Michael E ^a   Chen, Wei ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F FDOPA; Brain tumors; Ki 67 proliferation index; PET; Tumor grade

Indexed keywords

6 FLUORODOPA F 18; KI 67 ANTIGEN; 2,6 DIFLUORO 3,4 DIHYDROXYPHENYLALANINE; 2,6-DIFLUORO-3,4-DIHYDROXYPHENYLALANINE; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTROCYTOMA; BRAIN TISSUE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG UPTAKE; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR RECURRENCE; BRAIN TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; STATISTICS;

ADULT; AGED; BRAIN NEOPLASMS; DIHYDROXYPHENYLALANINE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 79851498484     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.078592     Document Type: Article

References (40)

1. McKeever PE, Ross DA, Strawderman MS, et al. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol. 1997;56:798-805. (Pubitemid 27280190)
2. Wakimoto H, Aoyagi M, Nakayama T, et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer. 1996;77:373-380. (Pubitemid 26025528)
3. Hoshino T, Ahn D, Prados MD, et al. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling. Int J Cancer. 1993;53:550-555. (Pubitemid 23069262)
4. Sallinen PK, Haapasalo HK, Visakorpi T, et al. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol. 1994;174:275-282.
5. Daumas-Duport C, Scheithauer BW, Kelly PJ. A histologic and cytologic method for the spatial definition of gliomas. Mayo Clin Proc. 1987;62:435-449.
6. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445. (Pubitemid 32207394)
7. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316-1322. (Pubitemid 28240345)
8. Laverman P, Boerman OC, Corstens FH, et al. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med Mol Imaging. 2002;29:681-690. (Pubitemid 34439330)
9. 11C]methionine. J Comput Assist Tomogr. 1983;7:1062-1066.
10. Mosskin M, von Holst H, Bergstrom M, et al. Positron emission tomography with 11C-methionine and computed tomography of intracranial tumours compared with histopathologic examination of multiple biopsies. Acta Radiol. 1987;28:673-681. (Pubitemid 18041770)
11. Pöpperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933-1942. (Pubitemid 350212135)
12. 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:176-182.
13. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
14. 18Ffluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging. 2008;35:2009-2017.
15. 18F-FDG. J Nucl Med. 2005;46:945-952.
16. 11Cmethylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948-1958.
17. 18F]3′-deoxy-3′- fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:653-659.
18. 11C-methionine-PET. J Clin Neurosci. 2005;12:775-780.
19. 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev. 1999;22:210-214.
20. Kim S, Chung JK, Im SH, et al. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2005;32:52-59. (Pubitemid 40142778)
21. Heiss WD, Wienhard K, Wagner R, et al. 18F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med. 1996;37:1180-1182. (Pubitemid 26329529)
22. 11C]methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561-1567.
23. 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47:904-911.
24. Tripathi M, Sharma R, D'Souza M, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med. 2009;34:878-883.
25. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol. 2009;71:242-248.
26. 18F-FDOPA kinetics in brain tumors. J Nucl Med. 2007;48:1651-1661.
27. Brix G, Zaers J, Adam LE, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med. 1997;38:1614-1623. (Pubitemid 27443965)
28. Lartizien C, Comtat C, Kinahan PE, et al. Optimization of injected dose based on noise equivalent count rates for 2- and 3-dimensional whole-body PET. J Nucl Med. 2002;43:1268-1278. (Pubitemid 34988777)
29. 18F]Fluoro-L-dopa. Int J Rad Appl Instrum [A]. 1992;43:989-996.
30. 18F] OF2. Nucl Med Biol. 1996;23:189-199.
31. Bergstrom M, Litton J, Eriksson L, et al. Determination of object contour from projections for attenuation correction in cranial positron emission tomography. J Comput Assist Tomogr. 1982;6:365-372.
32. Kinahan PE, Townsend DW, Beyer T, et al. Attenuation correction for a combined 3D PET/CT scanner. Med Phys. 1998;25:2046-2053.
33. Nuyts J, Michel C, Dupont P. Maximum-likelihood expectation-maximization reconstruction of sinograms with arbitrary noise distribution using NEC-transformations. IEEE Trans Med Imaging. 2001;20:365-375. (Pubitemid 32576600)
34. Kleihues P, Cavenee WK, eds. The WHO Classification of Tumors of the Nervous System. 1st ed. Lyon, France: IARC Press; 2000.
35. Sarantopoulos GP, Gui D, Shintaku P, et al. Immunohistochemical analysis of lung carcinomas with pure or partial bronchioloalveolar differentiation. Arch Pathol Lab Med. 2004;128:406-414. (Pubitemid 38451127)
36. Terasaki H, Niki T, Matsuno Y, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol. 2003;27:937-951. (Pubitemid 36758897)
37. 3H]methyl]-L-methionine. J Nucl Med. 2000;41:1250-1255.
38. 11C]methionine and rubidium-82 using PET. J Neurol Sci. 1995;132:20-27.
39. 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med. 2006;47:393-403.
40. Sasajima T, Miyagawa T, Oku T, et al. Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines. Eur J Nucl Med Mol Imaging. 2004;31:1244-1256. (Pubitemid 39222488)